Bone Biologics Files Q2 2024 10-Q

TL;DR

Bone Biologics dropped its Q2 10-Q. Check financials for the latest.

AI Summary

Bone Biologics Corp filed its 10-Q for the period ending June 30, 2024. The company, based in Burlington, MA, operates in the orthopedic, prosthetic & surgical appliances sector. The filing covers financial information for the second quarter and the first half of 2024, comparing it to the same periods in 2023.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for Bone Biologics Corp, crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a publicly traded company, Bone Biologics faces inherent market and operational risks, and the 10-Q provides details on its financial standing which could indicate potential risks.

Key Numbers

• 20240630 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
• 20240809 — Filing Date (Shows when the report was officially submitted to the SEC.)

Key Players & Entities

• Bone Biologics Corp (company) — Filer of the 10-Q
• Burlington, MA (location) — Company headquarters
• 20240630 (date) — End of reporting period
• 20240809 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value per share BBLG The Nasdaq

Filing Documents

• form10-q.htm (10-Q) — 723KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 11KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001493152-24-030982.txt ( ) — 4145KB
• bblg-20240630.xsd (EX-101.SCH) — 41KB
• bblg-20240630_cal.xml (EX-101.CAL) — 32KB
• bblg-20240630_def.xml (EX-101.DEF) — 139KB
• bblg-20240630_lab.xml (EX-101.LAB) — 346KB
• bblg-20240630_pre.xml (EX-101.PRE) — 248KB
• form10-q_htm.xml (XML) — 546KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION:

Financial Statements

Item 1. Financial Statements. F-1 Unaudited Condensed Consolidated Financial Statements Unaudited Condensed Consolidated Balance Sheets F-1 Unaudited Condensed Consolidated Statements of Operations F-2 Unaudited Condensed Consolidated Statements of Stockholders' Equity F-3 Unaudited Condensed Consolidated Statements of Cash Flows F-5 Notes to Unaudited Condensed Consolidated Financial Statements F-6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 4

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 9

Controls and Procedures

Item 4. Controls and Procedures 9

– OTHER INFORMATION

PART II – OTHER INFORMATION: 10

Legal Proceedings

Item 1. Legal Proceedings 10

Risk Factors

Item 1A. Risk Factors 10

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 10

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 10

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 10

Other Information

Item 5. Other Information 10

Exhibits

Item 6. Exhibits 11

Signatures

Signatures 12 2 NOTE ON FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Form 10-Q") contains forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. For a more detailed listing of some of the risks and uncertainties facing the Company, please see our Current Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC") on February 21, 2024 and subsequent Quarterly Reports on Form 10-Q or other reports filed with the SEC. All expenditures, cash flows, business strategy and plans and objectives of management for future operations are forward-looking statements. The words "anticipate," "believe," "expect," "plan," "estimate," "could," "may," "will," and similar expressions are intended to identify forward-looking statements. These statements include, among others, information regarding future operations, future capital expenditures, and future net cash flow. Such statements reflect our management's current views with respect to future events and financial performance and involve risks and uncertainties, including, without limitation, our ability to raise additional capital to fund our operations, inflation, rising interest rates, governmental responses there to and possible recession caused thereby,

forward-looking statements

forward-looking statements. Unless expressly indicated or the context requires otherwise, the terms "Company," "we," "us," and "our" in this document refer to Bone Biologics Corporation, a Delaware corporation and its wholly owned subsidiary as defined under the heading "Management's Discussion and Analysis" in this Form 10-Q. 3 PART I – FINANCIAL INFORMATION Item 1. Financial Statements. Bone Biologics Corporation Condensed Consolidated Balance Sheets June 30, 2024 December 31, 2023 (unaudited) Assets Current Assets Cash $ 2,332,068 $ 3,026,569 Advances on research and development contract services 650,275 328,844 Prepaid insurance 192,691 372,350 Prepaid expenses 18,430 10,000 Total current assets 3,193,464 3,737,763 Total assets $ 3,193,464 $ 3,737,763 Liabilities and Stockholders' Equity Current Liabilities Accounts payable and accrued expenses $ 231,872 $ 360,662 Research and development contract liabilities 44,980 - Accrued legal settlement - 414,989 Warrant liability 7,655 55,751 Total current liabilities 284,507 831,402 Total liabilities 284,507 831,402 Commitments and Contingencies - - Stockholders' Equity Preferred Stock, $ 0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at June 30, 2024 and December 31, 2023 - - Common stock, $ 0.001 par value per share; 100,000,000 shares authorized; 1,315,489 and 534,238 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 1,315 534 Additional paid-in capital 85,466,303 83,814,785 Accumulated deficit ( 82,558,661 ) ( 80,908,958 ) Total stockholders' equity 2,908,957 2,906,361 Total liabilities and stockholders' equity $ 3,193,464 $ 3,737,763 See accompanying notes to unaudited condensed consolidated financial statements. F-1 Bone Biologics Corporation Condensed Consolidated Statements of Operations Three Months Ended June 30, 2024 Thr

View Full Filing

View this 10-Q filing on SEC EDGAR